Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

664
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
664
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Tumor Progression02:07

Tumor Progression

7.9K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preoperative cardiovascular evaluation in patients with cancer.

Frontiers in cardiovascular medicine·2026
Same author

Sports Cardiology Care in the United States: Can We Fix Fractured Cardiac Care?

JACC. Advances·2026
Same author

QT monitoring in chemotherapy.

Frontiers in cardiovascular medicine·2026
Same author

LATS1/2-CD38 Metabolic Rewiring Links Senescence to Intraplaque Thrombosis.

Circulation research·2026
Same author

Cardiovascular Risk Prediction Across the Spectrum of Measured Physical Activity.

Journal of the American College of Cardiology·2026
Same author

Sex-Based Differences in the Etiology of Sudden Cardiac Arrest and Death Among Young Competitive Athletes From the United States.

JACC. Clinical electrophysiology·2026
Same journal

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting.

Future oncology (London, England)·2026
Same journal

Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis.

Future oncology (London, England)·2026
Same journal

Disparities in mortality among HER2-positive breast cancer patients treated with trastuzumab in Chile (2015-2024): real-world evidence from 4,920 cases.

Future oncology (London, England)·2026
Same journal

VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma.

Future oncology (London, England)·2026
Same journal

Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy.

Future oncology (London, England)·2026
Same journal

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia.

Future oncology (London, England)·2026
See all related articles

Related Experiment Video

Updated: Apr 6, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.3K

Cardio-oncology: an ongoing evolution.

Bradley J Petek1, Chris Greenman2, Joerg Herrmann3

  • 1School of Medicine, University of Washington, 1959 NE Pacific St, Seattle, WA 98195, USA.

Future Oncology (London, England)
|July 23, 2015
PubMed
Summary
This summary is machine-generated.

Modern cancer treatments improve survival but increase cardiovascular risks for patients. This has led to the rise of cardio-oncology programs to manage heart health in cancer survivors.

Keywords:
anthracyclinecancer therapycardio-oncologycardiotoxicity

More Related Videos

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.9K
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.6K

Related Experiment Videos

Last Updated: Apr 6, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.3K
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.9K
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.6K

Area of Science:

  • Cardiology
  • Oncology
  • Cardio-Oncology

Background:

  • Cancer survivorship has increased due to modern treatments.
  • Cancer survivors face a growing risk of cardiovascular events.
  • Multidisciplinary cardio-oncology programs are emerging to address this challenge.

Purpose of the Study:

  • To outline the current state of cardio-oncology.
  • To provide future perspectives for the discipline of cardio-oncology.

Main Methods:

  • Literature review on cardio-oncology development.
  • Analysis of trends in cancer treatment and cardiovascular risk.
  • Synthesis of current practices and future research directions.

Main Results:

  • Cardiovascular events are an increasing concern for cancer survivors.
  • Novel cancer therapies present ongoing cardiac risk management questions.
  • Cardio-oncology is evolving to address these complex patient needs.

Conclusions:

  • Cardio-oncology is a critical and expanding field.
  • Future research should focus on cardiac protection strategies.
  • Continued collaboration is essential for improving cancer survivor outcomes.